Intercept Pharmaceuticals to Provide 2013 Update on Clinical Programs for Obeticholic Acid on January 9

NEW YORK, Jan. 2, 2014 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, today announced that it will provide an update on the progress of its clinical development programs after theNASDAQ Market closes on January 9, 2014. This update will provide, among other items, information on the completion of the double-blind phase of the POISE trial, top line data from the OBADIAH and PESTO trials and 2014 anticipated milestones. Intercept management will conduct a conference call and audio webcast at 4:30 p.m. EDT on the same day.

Date: January 9, 2014

Time: 4:30 PM ET

Teleconference and webcast details will be available at: A replay of the call will be available on Intercept’s website approximately two hours after the completion of the call and will be archived for two weeks.

About Intercept

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver diseases utilizing its expertise in bile acid chemistry. The company’s lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is initially being developed for the second line treatment of primary biliary cirrhosis (PBC) in patients with an inadequate response to, or who are unable to tolerate, ursodiol, the only approved therapy for this indication. OCA has received orphan drug designation in both the United States and Europe for the treatment of PBC. Intercept owns worldwide rights to OCA outside of Japan and China, where it has out-licensed the product candidate to Dainippon Sumitomo Pharma. For more information about Intercept, please visit the Company’s website at:

Source: Intercept Pharmaceuticals, Inc.